Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics

J.G. Wildenbeest, on behalf of RESCEU WP4

Facts & Figures

- **Start date:** 01/01/2017
- **End date:** 31/12/2017
- **Contributions**
  - **IMI funding:** 14,498,125 €
  - **EFPIA in kind:** 14 673 665 €
  - **Total Cost:** 29 171 790 €
- **Project website:** www.resc-eu.org
- **Social media:** twitter@RESCEUproject

Challenge

Respiratory Syncytial Virus (RSV) infection causes severe disease in young infants, older adults and COPD patients. Expectations are that a vaccine will be available in the near future. There is a substantial gap in knowledge on RSV morbidity and associated healthcare and social costs across Europe.

Aim: To provide better insights into the impact of RSV on individuals, health systems and societies throughout Europe, and to actively engage stakeholders in order to improve strategic planning and decision-making.

Approach & Methodology

- **Birth Cohort study**
  - 10,000 healthy infants (1,000 active; 9,000 passive)
- **Older adult cohort study**
  - 1,000 adults ≥ 60 years of age
- **COPD cohort study**
  - 500 COPD patients

Value of IMI collaboration

- Active involvement of academia, EFPIA, public health institutions and patient organisations in the design and implementation of these studies.
- Active engagement of patient organisations from designing the study onwards.

Impact & take home message

RESCEU will provide unique burden of disease estimates of RSV disease in Europe which will help stakeholders and governments in Europe in decision making about implementation of RSV vaccines and therapeutics in the near future.

This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RESCEU grant no 116019).